ABT Abbott Laboratories
Trend channel, buy level and 3-month target. Information only, not financial advice.
Inside the channel · 2-year channel falling
Price is between the lines.
- 2-year channel
- US$98.05 – US$114.88 · falling, −12% a year
- Price in channel
- 49% (0% = floor, 100% = ceiling)
- Ceiling overhead
- US$114.88
- Turns bearish below
- US$98.05
What broke this trend
- The fall
- -40% from US$135.813 Mar 2025 → 11 May 2026
- Whose problem it was
- This company0 of 3 Medical - Devices peers fell with it
- Does it resolve?
- Temporary falls like it have resolved on the record
- Regained so far
- 45%of what it lost
- What the record says
- 78% of 999 comparable falls came back, typically in 85 days measured across every stock we hold history for, its peer group being too small
Fell -40% (3 Mar 2025 → 11 May 2026); regained 45% so far; company-specific.
Reported at the time: What Does the Market Think About Abbott Laboratories? — 28 Feb 2025
Price history, with the path projected 3 months forward
Updated 1:26 AM ET (9 h ago)
- Daily close
- Upper trend line (2 years)
- Lower trend line (2 years)
- Dashed after today: projected 3 months
- Our buy
- Our target
Our target
Hit rate too low on this symbol (2/10) — no published call or alerts; levels below are for reference.
Buy at or below
US$101.44
level as at 25 Nov 2026
Our target
US$109.55
by 10 Nov 2026
Projected move
8.0%
gross, before costs
Price is between our buy and target.
Target: ABT's usual move size (8.0%), the best return per day on this path.
10 settled calls · 2 reached target (20%) · average best move 5.8%. See the full record.
- Upper line touches
- 8
- Lower line touches
- 3
- Fit confidence
- 60%
- Fitted
- 1 Nov 2026
Company information
About Abbott Laboratories
Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Robert Ford
- Employees
- 115,000
- Country
- US
Scorecard
Our own scores from the fundamentals below (not Morningstar ratings).
- Valuation
- —
- Profitability
- —
- Financial health
- —
- Cash generation
- —
Key statistics
- Market cap
- US$178.40B
- Enterprise value
- —
- Beta
- 0.58
- Avg volume
- 10.49M
- Revenue per share
- —
- Dividend yield
- —
- 52-week range
- 81.97-132.03
- Exchange
- NYSE
Key ratios
- P/E (TTM)
- —
- PEG
- —
- Price / sales
- —
- Price / book
- —
- EV / EBITDA
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Current ratio
- —
- Quick ratio
- —
- Debt / equity
- —
- Interest cover
- —
Income statement
Balance sheet
Cash flow
Trend lines are fitted to past swing highs and lows and may not continue. Information only, not financial advice.